1Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
3Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Copyright © 2018 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In Table 1, the manufacturer of insulin degludec (Tresiba) was wrongly listed as Sanofi. This should be NovoNordisk.
In the subsection ‘INSULIN PREPARATIONS AND ADMINISTRATION,’ on page 6, insulin degludec (Tresiba) was mentioned, but without manufacturer, this should be NovoNordisk.
In the subsection ‘USE OF METFORMIN IN T1DM,’ page 7, the original text ‘reduction of progression of caroT1DM artery intima-media thickness,’ should be corrected to ‘reduction of progression of carotid artery intima-media thickness.’